Haemophilus influenzae Type B Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Haemophilus influenzae Type B Infections – Pipeline Review, H2 2019’, provides an overview of the Haemophilus influenzae Type B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Haemophilus influenzae Type B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Haemophilus influenzae Type B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Haemophilus influenzae Type B Infections

– The report reviews pipeline therapeutics for Haemophilus influenzae Type B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Haemophilus influenzae Type B Infections therapeutics and enlists all their major and minor projects

– The report assesses Haemophilus influenzae Type B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Haemophilus influenzae Type B Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Haemophilus influenzae Type B Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Haemophilus influenzae Type B Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Beijing Minhai Biotechnology Co Ltd

Biken Co Ltd

Biological E Ltd

Cadila Healthcare Ltd

CanSino Biologics Inc

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

KM Biologics Co Ltd

LG Chem Ltd

Liaoning Chengda Co., Ltd.

Novo Medi Sciences Pvt Ltd

Olymvax Biopharmaceuticals Inc

Panacea Biotec Ltd

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Tuck-More Biotechnology Co Ltd

Vaxxilon AG

Yisheng Biopharma Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Haemophilus influenzae Type B Infections - Overview

Haemophilus influenzae Type B Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Haemophilus influenzae Type B Infections - Therapeutics Assessment

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Haemophilus influenzae Type B Infections - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

Cadila Healthcare Ltd

Chongqing Zhifei Biological Products Co Ltd

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Kaketsuken

LG Chem Ltd

Panacea Biotec Ltd

Sanofi Pasteur SA

Serum Institute of India Ltd

Shantha Biotechnics Pvt Ltd

Wockhardt Ltd

Haemophilus influenzae Type B Infections - Drug Profiles

(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (acellular) + tetanus) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + Haemophilus influenza [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + Haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(diphtheria + tetanus + pertussis + poliomyelitis + Haemophilus influenzae [serotype B]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae [serotype B] + meningococcal [serotypes A, C]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(Haemophilus influenzae B + Neisseria meningitidis [serotypes A, C, Y, W135]) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BK-1310 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B (pentavalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae B vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

influenza vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KD-370 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LBVD - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LT-Hib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Haemophilus influenzae Type B Infections - Dormant Projects

Haemophilus influenzae Type B Infections - Discontinued Products

Haemophilus influenzae Type B Infections - Product Development Milestones

Featured News & Press Releases

Nov 24, 2016: Sanofi Pasteur launches India's first 6-in-1 pediatric vaccine- Hexaxim

Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5

Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine

May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization

Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima

Feb 22, 2013: Sanofi Pasteur Announces EMA's CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine

Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Haemophilus influenzae Type B Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Biken Co Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Biological E Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Cadila Healthcare Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by CanSino Biologics Inc, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by GlaxoSmithKline Plc, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by KM Biologics Co Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by LG Chem Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Liaoning Chengda Co., Ltd., H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Novo Medi Sciences Pvt Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Olymvax Biopharmaceuticals Inc, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Panacea Biotec Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Sanofi Pasteur SA, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Serum Institute of India Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Shantha Biotechnics Pvt Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Tuck-More Biotechnology Co Ltd, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Vaxxilon AG, H2 2019

Haemophilus influenzae Type B Infections – Pipeline by Yisheng Biopharma Co Ltd, H2 2019

Haemophilus influenzae Type B Infections – Dormant Projects, H2 2019

Haemophilus influenzae Type B Infections – Dormant Projects, H2 2019 (Contd..1), H2 2019

Haemophilus influenzae Type B Infections – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports